



CERTIFICATE



This is to certify that the company

Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH

Brunner Str. 67 1230 Wien Austria

with the organizational units/sites as listed in the annex

has implemented and maintains a Quality Management System.

Scope of certification:

Development, production and distribution of in-vitro diagnostics and analysing systems for haemostasis, protein and immune diagnostics.

-AUS (a), BRA, CND, JPN, USA (a,b,c,d)

Through an audit, documented in a report, performed by DQS Medizinprodukte GmbH, it was verified that the management system fulfills the requirements of the following standard:

ISO 13485: 2016

including applicable country-specific regulatory requirements, as indicated below the scope (full references of abbreviations are listed in the annex)

Certificate registration no. 543530 MDSAP16

Certificate unique ID 170779833
Effective date 2023-02-04
Expiry date 2026-02-03
Frankfurt am Main 2022-12-11



DQS Medizinprodukte GmbH

Melens

Sigrid Uhlemann Managing Director

Marc Goedecke Product Manager





Annex to certificate

Certificate registration No.: 543530 MDSAP16

Certificate unique ID: 170779833

Effective date: 2023-02-04

Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH

Brunner Str. 67 1230 Wien Austria

Audited site

REPs FEI No.: site scope and country-specific requirements

543530

Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH

Brunner Str. 67 1230 Wien Austria Development, production and distribution of in-vitro diagnostics and analysing systems for haemostasis, protein and immune diagnostics.

-AUS (a), BRA, CND, JPN, USA (a,b,c,d)

REPs FEI No.: F004534



Annex to certificate

Certificate registration No.: 543530 MDSAP16

Certificate unique ID: 170779833

Effective date: 2023-02-04

Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH

Brunner Str. 67 1230 Wien Austria

Full references of country-specific requirements of MDSAP participating Regulatory Authorities

Abbreviation	Jurisdiction	Reference
AUS	Australia	 (a) Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 3, Part 1 – Full Quality Assurance Procedure (b) Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 3, Part 4 – Production Quality Assurance Procedure
BRA	Brazil	RDC ANVISA n. 665/2022 RDC ANVISA n. 551/2021 RDC ANVISA n. 67/2009
CND	Canada	Medical Device Regulations SOR/98-282, Part 1
JPN	Japan	MHLW Ministerial Ordinance No. 169 (2004) as amended by MHLW Ordinance No. 128 (2014), Articles 4 to 68 Japan PMD Act (as applicable)
USA	United States	(a) 21 CFR Part 803 (b) 21 CFR Part 806 (c) 21 CFR Part 807 (d) 21 CFR Part 820 (e) 21 CFR Part 821